ProImmune unveils self-loading MHC Class I monomers for enhanced T cell research
ProImmune Ltd has introduced ProVE SL Self-Loading MHC Class I Monomers, a new platform designed to provide researchers with greater flexibility in antigen-specific CD8+ T cell detection studies.
Extended allele coverage for diverse research needs
The empty, biotinylated MHC Class I molecules offer an expanded allele range covering more than 50 HLA types, including HLA-A, HLA-B, HLA-C, non-canonical alleles, and mouse H-2. This breadth enables researchers to study donor cohorts with less common HLA types, addressing a significant limitation of conventional pre-loaded MHC monomers that typically focus on frequent alleles.
The self-loading platform allows researchers to load their own peptides and combine monomers with various avidin or streptavidin conjugates, including fluorescent, barcoded, or mass-cytometry reagents. This capability facilitates the creation of tetramers or surface-bound complexes tailored to specific experimental requirements.
Streamlined workflow integration
The ProVE SL system supports integration with flow cytometry, mass cytometry, and single-cell RNA sequencing workflows. By eliminating the constraints of pre-loaded systems, which often restrict peptide choice and require complex loading steps, the platform enables faster experimental setup and panel reconfiguration.
The technology addresses growing demands in T cell immunology, epitope mapping, and immune-monitoring work-flows that require rapid customisation across diverse HLA contexts. Researchers can adapt their reagents more quickly to study new antigens relevant to infectious diseases, cancer neo-antigens, autoantigens, and vaccine response measurements.
“With the launch of our new ProVE SL monomers, we are offering researchers the ability to customise MHC monomer reagents at unprecedented speed and breadth,” said Dr Nikolai Schwabe, chief executive officer at ProImmune. “This flexibility will accelerate epitope mapping, immune-monitoring and translational across research programmes, including in infectious disease and oncology.”
Dr Schwabe noted that the ProVE SL monomers represent a natural extension to the company’s existing product portfolio in MHC Class I and II monomers, multimers, immunology services, and peptide synthesis capabilities.
The ProVE SL Self-Loading MHC Class I
Monomers are now available through ProImmune’s catalogue and distributor network.
For more information, visit: https://shorturl.at/8gHy8
Digital issue: Please click here for more information
